What do we know about the outcome of concomitant MPN and COVID-19?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee members Laura Michaelis, Medical...

COVID-19: Implications for patients with myeloproliferative neoplasms

Summary of two presentations at the Texas Virtual MPN Workshop (TMW) 2020: First Annual Workshop and Meeting. The first from MPN...

What is the news about ropeginterferon?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...

What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University...

Understanding the pathology of MPN: The value of in vivo and in vitro models

Among chronic Philadelphia-negative myeloproliferative neoplasms (MPN), polycythemia vera (PV) is considered the most...

The long-term efficacy of interferon alpha in targeting different driver mutations involved in MPN

Mutations in JAK2V617F, calreticulin (CALR), and thrombopoietin receptor (MPL) genes are three main...

Calreticulin haploinsufficiency is needed for the induction of MPN-like pathology in vitro

Mutant CALR has been shown to bind to MPL and activate downstream signaling pathways that lead to the...

Fedratinib in myelofibrosis

Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with...

PTG-300 receives orphan drug designation from EMA for the treatment of PV

The European Medicines Agency (EMA) has granted orphan drug designation to PTG-300 for the treatment of polycythemia vera (PV).

U.S. FDA grants orphan drug designation for PTG-300 for the treatment of polycythemia vera

PTG-300, an injectable hepcidin mimetic peptide, has received orphan drug designation by the U.S. Food and...